<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031642</url>
  </required_header>
  <id_info>
    <org_study_id>535-00</org_study_id>
    <secondary_id>CDR0000069211</secondary_id>
    <secondary_id>NCI-V02-1691</secondary_id>
    <nct_id>NCT00031642</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation</brief_title>
  <official_title>Phase I/II Study of IDEC-Y2B8 (Zevalin) for Post Transplant Relapses of B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver&#xD;
      cancer-killing substances to them without harming normal cells. Radiolabeled monoclonal&#xD;
      antibodies can locate and deliver radioactive cancer-killing substances.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal&#xD;
      antibodies with rituximab in treating patients who have non-Hodgkin's lymphoma that has not&#xD;
      responded to high-dose chemotherapy and autologous stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of yttrium Y 90-labeled ibritumomab tiuxetan when&#xD;
           administered with rituximab in patients with B-cell non-Hodgkin's lymphoma who have&#xD;
           relapsed after high-dose chemotherapy and autologous hematopoietic stem cell&#xD;
           transplantation.&#xD;
&#xD;
        -  Determine the safety and efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of yttrium Y 90-labeled ibritumomab tiuxetan&#xD;
      (IDEC-Y2B8).&#xD;
&#xD;
        -  Phase I: Patients receive rituximab IV over 4-6 hours followed by indium In 111-labeled&#xD;
           ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0. Patients receive&#xD;
           rituximab IV again on day 7 followed by IDEC-Y2B8 IV over 10 minutes.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of IDEC-Y2B8 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose at which 3 of 6 patients experience&#xD;
      dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Once the MTD is determined, 58 additional patients are treated at that dose&#xD;
           level as in phase I.&#xD;
&#xD;
      Patients are followed at 6 weeks, every 3 months for 1 year, every 6 months for 2 years, and&#xD;
      then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 78 patients (20 for phase I and 58 for phase II) will be&#xD;
      accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
  </primary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of relapsed B-cell non-Hodgkin's lymphoma (NHL) after high-dose chemotherapy&#xD;
             and autologous stem cell transplantation&#xD;
&#xD;
          -  Less than 25% bone marrow involvement with NHL as evidenced by unilateral or bilateral&#xD;
             biopsy within the past 6 weeks&#xD;
&#xD;
               -  Bone marrow biopsy should demonstrate 15-20% of cellular space occupied by normal&#xD;
                  hematopoiesis&#xD;
&#xD;
          -  CD20 antigen expression in tumor tissue within the past year as evidenced by 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Immunoperoxidase stains of tissue showing positive reactivity with L26 antibody&#xD;
&#xD;
               -  Flow cytometry studies&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  More than 2 cm bidimensionally&#xD;
&#xD;
          -  No active CNS lymphoma&#xD;
&#xD;
          -  No HIV- or AIDS-related lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  19 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 150,000/mm^3&#xD;
&#xD;
          -  No transfusion dependency&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT or SGPT no greater than 2.5 times upper limit of normal (unless due to&#xD;
             lymphomatous infiltration of the liver)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
          -  No active obstructive hydronephrosis&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             therapy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection requiring oral or IV antibiotics&#xD;
&#xD;
          -  No human antimurine antibody positivity&#xD;
&#xD;
          -  No other major medical problems&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior growth factors&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  No dependency on hematopoietic growth factors (e.g., epoetin alfa, interleukin-11,&#xD;
             filgrastim [G-CSF], or sargramostim [GM-CSF])&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
          -  No other concurrent biologic therapy of any kind&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since any prior cytotoxic chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No prior fludarabine&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroids except as maintenance for non-cancerous disease&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of estimated bone marrow reserve&#xD;
&#xD;
          -  No concurrent external beam radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior immunosuppressants&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anti-cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie M. Vose, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Julie M Vose, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

